Related references
Note: Only part of the references are listed.A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR
M. F. Kaiser et al.
LEUKEMIA (2013)
Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y Trials
Bruno Paiva et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Cyclin-Dependent Kinase Inhibitor p21Waf1: Contemporary View on Its Role in Senescence and Oncogenesis
V. S. Romanov et al.
BIOCHEMISTRY-MOSCOW (2012)
Prediction of cytogenetic abnormalities with gene expression profiles
Yiming Zhou et al.
BLOOD (2012)
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
Laura Rosinol et al.
BLOOD (2012)
Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders
Fiona M. Ross et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
A gene expression signature for high-risk multiple myeloma
R. Kuiper et al.
LEUKEMIA (2012)
DKK1 as a novel target for myeloma immunotherapy
Jianfei Qian et al.
ONCOIMMUNOLOGY (2012)
The genetic architecture of multiple myeloma
Gareth J. Morgan et al.
NATURE REVIEWS CANCER (2012)
Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone
Shaji K. Kumar et al.
BLOOD (2011)
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance
Mara-Victoria Mateos et al.
BLOOD (2011)
The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma
Luca Agnelli et al.
CLINICAL CANCER RESEARCH (2011)
The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells
Lucia Lopez-Corral et al.
CLINICAL CANCER RESEARCH (2011)
HSP90 Inhibitors as Therapy for Multiple Myeloma
Saad Z. Usmani et al.
Clinical Lymphoma Myeloma & Leukemia (2011)
Genomic biomarkers in predictive medicine. An interim analysis
Richard Simon
EMBO MOLECULAR MEDICINE (2011)
Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients
Maria E. Sarasquete et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy
Mark van Duin et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The prognostic significance of cytogenetics and molecular profiling in multiple myeloma
Jeffrey R. Sawyer
CANCER GENETICS (2011)
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance
Bijay Nair et al.
BLOOD (2010)
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients
Annemiek Broyl et al.
BLOOD (2010)
Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome
Nicholas J. Dickens et al.
CLINICAL CANCER RESEARCH (2010)
The ARF tumor suppressor: structure, functions and status in cancer
Peggy Ozenne et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
R. Fonseca et al.
LEUKEMIA (2009)
Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients:: A study of the intergroupe francophone du myelome
Olivier Decaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition
Wee J. Chng et al.
BLOOD (2008)
Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma
C. S. Chim et al.
LEUKEMIA (2007)
Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma
Christina M. Annunziata et al.
CANCER CELL (2007)
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
George Mulligan et al.
BLOOD (2007)
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
John D. Shaughnessy et al.
BLOOD (2007)
The molecular classification of multiple myeloma
Fenghuang Zhan et al.
BLOOD (2006)
Molecular pathogenesis and a consequent classification of multiple myeloma
PL Bergsagel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
PL Bergsagel et al.
BLOOD (2005)
Prognostic implications of p21 (Waf1/Cip1) immunolocalization in multiple myeloma
Masahiko Ohata et al.
BIOMEDICAL RESEARCH-TOKYO (2005)
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma
EM Hurt et al.
CANCER CELL (2004)
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript
M Santra et al.
BLOOD (2003)
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes
Jo Vandesompele et al.
GENOME BIOLOGY (2002)
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
FH Zhan et al.
BLOOD (2002)
Share Paper
